首页> 外文期刊>Cadernos de Saúde Pública >Treatment of postmenopausal osteoporosis in women: a systematic review
【24h】

Treatment of postmenopausal osteoporosis in women: a systematic review

机译:治疗妇女后绝经骨质疏松症:系统审查

获取原文
       

摘要

Osteoporosis, a typical disease of the elderly, has become a frequent and relevant public health problem. Several drugs are available for treatment of osteoporosis, some of which are currently dispensed by the Brazilian Unified National Health System. The objective of this study was to present a systematic review of drugs for treatment of osteoporosis, focusing on the adequacy of clinical protocols based on existing evidence in the scientific literature. We conducted a search for randomized clinical trials in PubMed and LILACS that presented results for bone mineral density, incidence of vertebral fractures, and adverse effects. 32 articles met the review's inclusion criteria. Bisphosphonates were reported to have consistently reduced the risk of vertebral fractures. Hormone replacement therapy showed positive outcomes, but its use has been found to increase the risk of cardiovascular disease and breast cancer. Teriparatide and monofluorophosphate also showed efficacy against osteoporosis. Calcium and vitamin D were given to patients as food supplements.
机译:骨质疏松症,老年人的典型疾病,已成为常见和相关的公共卫生问题。几种药物可用于治疗骨质疏松症,其中一些目前被巴西统一的国家卫生系统分配。本研究的目的是对治疗骨质疏松症的药物进行系统审查,重点是基于科学文献中现有证据的临床协议的充分性。我们在PubMed和Lilacs中进行了随机临床试验,呈现出骨矿物密度,椎体裂缝发病率和不利影响的结果。 32篇文章符合审查的纳入标准。据报道,双膦酸盐始终降低了椎体骨折的风险。激素替代疗法显示出阳性结果,但已经发现其使用增加了心血管疾病和乳腺癌的风险。 Teriparatide和单氟磷酸盐还显示出对骨质疏松症的功效。钙和维生素D作为食品补充剂给予患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号